Market revenue in 2023 | USD 185.5 million |
Market revenue in 2030 | USD 387.8 million |
Growth rate | 11.1% (CAGR from 2023 to 2030) |
Largest segment | Surgery |
Fastest growing segment | Intralesional injections |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Radiotherapy (RT), Intralesional injections, Intravenous Medications, Chemical peeling treatment, Surgery, Topical chemotherapy, Oral Medications |
Key market players worldwide | Bausch Health Companies Inc, Almirall SA, Genentech, Novartis AG ADR, Regeneron Pharmaceuticals Inc, Dr Reddy's Laboratories Ltd ADR, Taro Pharmaceuticals, Accord Healthcare |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to basal cell carcinoma treatment market will help companies and investors design strategic landscapes.
Surgery was the largest segment with a revenue share of 35.85% in 2023. Horizon Databook has segmented the Germany basal cell carcinoma treatment market based on radiotherapy (rt), intralesional injections, intravenous medications, chemical peeling treatment, surgery, topical chemotherapy, oral medications covering the revenue growth of each sub-segment from 2018 to 2030.
Skin cancer is a prevalent issue in Germany, with approximately 300,000 new cases reported each year. The majority of these cases are non-melanocytic types, such as basal cell and squamous cell carcinomas.
However, malignant melanoma, although less common, accounts for about 75% of the approximately 4,000 skin cancer-related deaths annually in Germany.
To address this significant health concern and reduce the burden of disease & mortality, biennial early skin cancer detection, known as Skin Cancer Screening (SCS), was implemented on July 1, 2008. This screening program is specifically aimed at statutorily insured individuals aged 35 and above.
Horizon Databook provides a detailed overview of country-level data and insights on the Germany basal cell carcinoma treatment market , including forecasts for subscribers. This country databook contains high-level insights into Germany basal cell carcinoma treatment market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account